Works Cited

1. Federation of State Medical Boards. Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: The Federation of State Medical Boards; 2013.

2. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.

3. PR Newswire. U.S. Public and Doctors' Misperceptions Revealed in National Survey Demonstrate Urgent Need for Increased Opioid Dependence Awareness. Available at https://www.prnewswire.com/news-releases/us-public-and-doctors-misperceptions-revealed-in-national-survey-demonstrate-urgent-need-for-increased-opioid-dependence-awareness-210981471.html. Last accessed July 17, 2018.

4. Leavitt SB. Survey Shows Opioid "Addiction" Misunderstood. Available at http://updates.pain-topics.org/2013/06/survey-shows-opioid-addiction.html?pfstyle=wp. Last accessed August 16, 2016.

5. Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22(9):1859-1865.

6. Mezei L, Murinson BB. Pain education in North American medical schools. J Pain. 2011;12:1199-208.

7. Oliver J, Coggins C, Compton P, et al. American Society for Pain Management Nursing position statement: pain management in patients with substance use disorders. Pain Management Nursing. 2012;13:169-183.

8. American Psychiatric Association. Highlights of Changes from DSM-IV-TR to DSM-5. Available at http://www.dsm5.org/documents/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf. Last accessed August 16, 2016.

9. Leavitt SB. APA Finally Gets Opioid "Addiction" Sorted Out. Available at http://updates.pain-topics.org/2010/03/apa-finally-gets-opioid-addiction.html?pfstyle=wp. Last accessed August 16, 2016.

10. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/resources/definition-of-addiction. Last accessed July 17, 2018.

11. Giordano J, Schatman ME, Höver G. Ethical insights to rapprochement in pain care: bringing stakeholders together in the best interest(s) of the patient. Pain Physician. 2009;12:E265-E275.

12. Kenen K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Medicine. 2012;6(2)e41.

13. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15:ES119-ES133.

14. Atkinson TJ, Schatman ME, Fudin J. The damage done by the war on opioids: the pendulum has swung too far. J Pain Res. 2014;7:265-268.

15. Webster LR. Pain and suicide: the other side of the opioid story. Pain Med. 2014;15(3):345-346.

16. Ziegler SJ. Patient abandonment in the name of opioid safety. Pain Med. 2013;14(3):323-324.

17. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2010.

18. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

19. Sundwall DN, Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2009.

20. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116.

21. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_opioids_2016-04-26_Patient_Counseling_Document.pdf. Last accessed July 17, 2018.

22. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442.

23. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.

24. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

25. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S16.

26. Katz NP. Opioid Prescribing Toolkit: A Workbook for Clinicians. New York, NY: Oxford University Press; 2010.

27. Strickland JM, Huskey A, Brushwood DB. Pharmacist-physician collaboration in pain management practice. J Opioid Manag. 2007;3:295-301.

28. American Chronic Pain Association. ACPA Resource Guide to Chronic Pain Medication and Treatment: 2018 Edition. Available at https://www.theacpa.org/wp-content/uploads/2018/03/ACPA_Resource_Guide_2018-Final-v2.pdf. Last accessed July 17, 2018.

29. Crespi-Lofton J. VIGIL: answer the question "Is it legitimate?" Pharmacy Today. 2006;12(1):1.

30. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26:552-561.

31. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence-based approach. Pain Physician. 2012;15:ES177-ES189.

32. Florida Legislature. 893.055 Prescription Drug Monitoring Program. Available at http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.055.html. Last accessed July 17, 2018.

33. Baxter J. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at http://www.drugabuse.gov/nidamed/centers-excellence/resources/minimizing-misuse-prescription-opioids-in-patients-chronic-nonmalignant-pain. Last accessed July 17, 2018.

34. American College of Preventive Medicine. Use, Abuse, Misuse and Disposal of Prescription Pain Medication Clinical Reference. Available at https://c.ymcdn.com/sites/www.acpm.org/resource/resmgr/timetools-files/painmedsclinicalreference.pdf. Last accessed July 17, 2018.

35. Office of National Drug Control Policy. Proper Disposal of Prescription Drugs. Available at https://www.ncjrs.gov/ondcppubs/publications/pdf/prescrip_disposal.pdf. Last accessed July 17, 2018.

36. Centers for Disease Control and Prevention. Risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.

37. Hannon K. The Prescription Drug Crisis in New York State: A Comprehensive Approach. Available at https://www.scribd.com/doc/82474334/Prescription-Drug-Abuse-Crisis-in-NYS-Comprehensive-Approach-New. Last accessed July 17, 2018.

38. U.S. Drug Enforcement Administration. Drug Scheduling. Available at https://www.dea.gov/druginfo/ds.shtml. Last accessed July 17, 2018.

39. Florida Legislature. Chapter 893: Drug Abuse Prevention and Control. Available at http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html. Last accessed July 17, 2018.

40. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR. 2016;65(1):1-49.

41. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434-442.

42. Lexicomp Online. Available at http://online.lexi.com. Last accessed July 17, 2018.

43. NewsWise. Nonmedical Use of Prescription Pain Relievers May Raise the Risk of Turning to Heroin Use. Available at http://www.amcp.org/uploadedFiles/Production_Menu/Policy_Issues_and_Advocacy/Policy_Resource_Center/Toolkits/Opioids/aug2013_newswise.pdf. Last accessed July 17, 2018.

44. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.

45. Meier B. Increase in Urine Testing Raises Ethical Questions. Available at https://www.nytimes.com/2013/08/02/business/increase-in-urine-testing-raises-ethical-questions.html?_r=0. Last accessed July 17, 2018.

46. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.

47. Holliday S, Hayes C, Dunlop A. Opioid use in chronic non-cancer pain. Part 2: prescribing issues and alternatives. Australian Family Physician. 2013;42:104-111.

48. U.S. Department of Justice Diversion Control Division. Don't Be Scammed By A Drug Abuser. Available at https://www.deadiversion.usdoj.gov/pubs/brochures/drugabuser.htm. Last accessed July 17, 2018.

49. Florida Department of Health. 2016–2017 Prescription Drug Monitoring Program Annual Report. Available at http://www.floridahealth.gov/statistics-and-data/e-forcse/funding/2017pdmpannualreport.pdf. Last accessed July 17, 2018.

50. Wheeler E, Davidson PJ, Jones TS, Irwin KS. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR. 2012;61(6):101-105.

51. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes—Florida, 2010–2012. MMWR. 2014;63(26):569-574.

52. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. 2016;64(50):1378-1382.

53. van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.

54. Florida Legislature. 381.887 Emergency Treatment for Suspected Opioid Overdose. Available at http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399/0381/Sections/0381.887.html. Last accessed July 17, 2018.

55. American Medical Association. Code of Ethics: Opinion 1.1.5 Terminating a Patient-Physician Relationship. Available at https://www.ama-assn.org/delivering-care/terminating-patient-physician-relationship. Last accessed July 17, 2018.

56. Bolen J. Discharging Patients Who Abuse Controlled Substances. Available at https://www.painmedicinenews.com/Policy-Management/Article/04-06/Discharging-Patients-Who-Abuse-Controlled-Substances/4340. Last accessed July 17, 2018.

57. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. What is a Prescriber's Role in Preventing the Diversion of Prescription Drugs? Available at http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Provider-Education-Toolkits/Downloads/prescriber-role-drugdiversion.pdf. Last accessed August 16, 2016.

58. Gutstein HB, Akil H. Opioid analgesics. In: Brunton L, Parker K, Lazo J, Buxton I, Blumenthal D (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011: 547-590.

59. Reuben DB, Alvanzo AAH, Ashikaga T, et al. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med. 2015;162(4):295-300.

60. Leavitt SB. Survey Shows Opioid "Addiction" Misunderstood. Available at http://updates.pain-topics.org/2013/06/survey-shows-opioid-addiction.html. Last accessed August 31, 2016.

61. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015;8:153-158.

62. Fudin J, Pratt Cleary J, Schatman ME. The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development. J Pain Res. 2016;9:153-156.

63. Long D. Pharmaceutical Trends, Issues, and Outlook. Available at http://performrx.com/sites/default/files/Long-Charting%20the%20Course%20for%20Change.pdf. Last accessed July 17, 2018.

64. National Forensic Laboratory Information System. Special Report: Opiates and Related Drugs Reported in NFLIS, 2009–2014. Available at https://www.deadiversion.usdoj.gov/nflis/spec_rpt_opioids_2014.pdf. Last accessed July 17, 2018.

65. Hwang CS, Kang EM, Kornegay CJ, Staffa JA, Jones CM, McAninch JK. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002–2014. Am J Prev Med. 2016;51(2):151-160.

66. Gill R. Outpatient Drug Utilization Patterns for Selected Opioid Analgesics in the U.S., Years 2007–2011. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM333218.pdf. Last accessed September 1, 2016.

67. Auth D. Considerations for Modifications to the ER/LA Opioid Analgesic REMS. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM501048.pdf. Last accessed July 17, 2018.

68. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. 2016;64(50):1378-1382.

69. Carter D. CDC advisory warns of possible nationwide increase in fentanyl deaths. Am J Nurs. 2016;116(2):15.

70. Hedegaard H, Chen LH, Warner M. Drug-poisoning deaths involving heroin: United States, 2000–2013. NCHS Data Brief. 2015;190:1-8.

71. Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths—27 states, 2013–2014. MMWR. 2016;65(33):837-843.

72. Drug Enforcement Administration. National Heroin Threat Assessment Summary: Updated. Available at https://www.dea.gov/divisions/hq/2016/hq062716_attach.pdf. Last accessed July 17, 2018.

73. Jamison RN, Scanlan E, Matthews ML, Jurcik DC, Ross EL. Attitudes of primary care practitioners in managing chronic pain patients prescribed opioids for pain: a prospective longitudinal controlled trial. Pain Med. 2016;17(1):99-113.

74. Anson P. Health Officials Call for Better Access to Addiction Treatment. Available at http://nationalpainreport.com/health-officials-call-for-better-access-to-addiction-treatment-8823738.html. Last accessed July 17, 2018.

75. Aronoff G. Take My Pain Away: A Physician's Perspective of Prescription Opioids and Pain Management. Available at http://www.theatlantic.com/sponsored/purdue-health/take-my-pain-away/202/. Last accessed September 1, 2016.

76. Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage. 2014;47(2):283-297.

77. Fudin J. The Hydrocodone Question. Available at http://www.drugtopics.com/drug-topics/content/tags/hydrocodone/hydrocodone-question. Last accessed July 17, 2018.

78. Florida Governor Rick Scott. 17-146 Executive Order directing a Public Health Emergency re: Opioid Epidemic. Available at https://www.flgov.com/wp-content/uploads/orders/2017/EO_17-146.pdf. Last accessed July 17, 2018.

79. Hall J. Florida Drug Trends Update: November 2015. Available at https://slideplayer.com/slide/12804922/. Last accessed July 17, 2018.

80. Popovich N. A Deadly Crisis: Mapping the Spread of America's Drug Overdose Epidemic. Available at https://www.theguardian.com/society/ng-interactive/2016/may/25/opioid-epidemic-overdose-deaths-map. Last accessed July 17, 2018.

81. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-691.

82. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98.

83. National Forensic Laboratory Information System. 2015 Midyear Report. Available at https://www.deadiversion.usdoj.gov/nflis/NFLIS_MidYear2015.pdf. Last accessed July 17, 2018.

84. Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths—United States, 2010. MMWR. 2014;63(40):881-885.

85. Ruhm CJ. Drug poisoning deaths in the United States, 1999–2012: a statistical adjustment analysis. Popul Health Metr. 2016;14:2.

86. Webster L. Will CDC Opioid Guidelines Help Reduce Overdoses? Available at https://www.painnewsnetwork.org/stories/2016/4/25/will-cdc-opioid-guidelines-help-reduce-overdoses. Last accessed July 17, 2018.

87. Ciccone TG, Kean N. Responses and Criticisms Over New CDC Opioid Prescribing Guidelines. Available at https://www.practicalpainmanagement.com/resources/news-and-research/responses-criticisms-over-new-cdc-opioid-prescribing-guidelines. Last accessed July 17, 2018.

88. Samp RA. Letter to the CDC ATS DR. Available at http://www.wlf.org/upload/litigation/misc/CDCFOIARequest-Opioids.pdf. Last accessed July 17, 2018.

89. Twillman B. Academy's Response: CDC's Guideline for Prescribing Opioids for Chronic Pain. Available at http://blog.aapainmanage.org/academys-response-center-disease-controls-guideline-prescribing-opioids-chronic-pain/. Last accessed September 1, 2016.

90. American Academy of Pain Medicine. CDC Guideline for Prescribing Opioids for Chronic Pain: A Statement from the American Academy of Pain Medicine. Available at http://www.painmed.org/files/aapm-statement-cdc-guideline-for-prescribing-opioids-for-chronic-pain.pdf. Last accessed July 17, 2018.

91. Alford DP. Opioid prescribing for chronic pain: achieving the right balance through education. N Engl J Med. 2016;374(4):301-303.

92. Wallwork RS, Chipidza FE, Stern TA. Obstacles to the prescription and use of opioids. Prim Care Companion CNS Disord. 2016;18(1):10.

93. Sloan P. Update on extended-release opioids in pain management. Expert Opin Drug Deliv. 2014;11(2):155-158.

94. Federation of State Medical Boards. Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: Federation of State Medical Boards; 2013.

95. Cheatle MD, Barker C. Improving opioid prescription practices and reducing patient risk in the primary care setting. J Pain Res. 2014;7:301-311.

96. Nadeau SE. Opioids for chronic noncancer pain. To prescribe or not to prescribe: what is the question? Neurology. 2015;85(7):646-651.

97. Florida Department of Law Enforcement. Drugs Identified in Deceased Persons by Florida Medical Examiners: 2016 Annual Report. Available at https://www.fdle.state.fl.us/MEC/Publications-and-Forms/Documents/Drugs-in-Deceased-Persons/2016-Annual-Drug-Report.aspx. Last accessed July 17, 2018.

98. Scott J. Florida’s New Law on Controlled Substance Prescribing. Available at https://flmedical.org/Florida/Florida_Public/Docs/FMA-Opioid-HB21.pdf. Last accessed July 17, 2018.

99. The Florida Senate. CS/CS/HB 21: Controlled Substances. Available at https://www.flsenate.gov/Session/Bill/2018/21. Last accessed July 17, 2018.

100. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.

101. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181-186.

102. National Comprehensive Cancer Network. Adult Cancer Pain, 2018. Available at https://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Last accessed July 17, 2018.

103. Dalal S, Bruera E. Assessment and management of pain in the terminally ill. Prim Care Clin Office Pract. 2011;38:195-223.

104. Berger AM, Shuster JL, Von Roenn JH (eds). Principles & Practice of Palliative Care & Supportive Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

Evidence-Based Practice Recommendations Citations

1. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116. Available at http://painphysicianjournal.com/2012/july/2012;%2015;S67-S116.pdf. Last accessed July 17, 2018.


Copyright © 2019 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.